Pharma Pulse 4/4/25: What Racial Color-Blindness Means for Trial Participation, Insights from the 2025 Pharmacy in Focus Report & more
The latest news for pharma industry insiders.
What Does Racial Color-Blindness Mean for Clinical Trial Participation?
Research collaboration between Tufts and the Society for Clinical Research Sites explores the prevalence of this belief in healthcare.
The GLP-1 Conundrum: Insights from the 2025 Pharmacy in Focus Report
Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.
Pharma’s Tariff Reprieve Will Be Temporary as More Levies Loom
The drug industry won a reprieve from sweeping tariffs announced by President Donald Trump on Wednesday, though it could be short-lived as the White House moves forward with plans for future levies on pharmaceutical imports.
Unlearn has announced results from a collaboration with remynd. The results were shared at the 2025 Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The collaboration focused on remynd’s Phase IIa clinical trial of REM127, an investigational, first-generation small molecule therapy targeting septins in patients with mild-to-moderate Alzheimer’s Disease (AD). The study enrolled a limited number of participants and measured changes in AD biomarkers over a short treatment window.
Artiva Biotherapeutics on LinkedIn
Our CEO Fred Aslan sat down with Pharmaceutical Executive to discuss Artiva’s allogeneic NK cell therapies. In this five-part interview series, he shares insights on our dual clinical trial strategy and how AlloNK® may improve the treatment of serious autoimmune diseases by providing a deep B-cell depletion with a better tolerability profile.
Key topics covered:
🔹 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗻𝗴 𝗔𝗹𝗹𝗼𝗡𝗞 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆: How we are advancing AlloNK as a novel treatment across across autoimmune diseases https://lnkd.in/ggMk2iMb
🔹 “𝗜𝗺𝗺𝘂𝗻𝗲 𝗥𝗲𝘀𝗲𝘁” 𝗶𝗻 𝗦𝗟𝗘/𝗟𝗡: Our NK cell therapy approach in systemic lupus erythematosus / lupus nephritis https://lnkd.in/g28JR_nW
🔹 𝗔𝗿𝘁𝗶𝘃𝗮’𝘀 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗧𝗿𝗶𝗮𝗹𝘀: A closer look at our ongoing clinical programs https://lnkd.in/gJ2xG6nC
🔹𝗗𝘂𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: Balancing company-sponsored and investigator-initiated trials to maximize clinical insights https://lnkd.in/gNauYshM
🔹 𝗙𝗗𝗔 𝗙𝗮𝘀𝘁 𝗧𝗿𝗮𝗰𝗸: The impact of Fast Track designation on the development of AlloNK https://lnkd.in/gD_CavQ5
Thank you to Miranda Schmalfuhs for showcasing the innovation and momentum behind Artiva’s work in NK cell therapy for autoimmune disease!
#AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
